Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Industry: Healthcare

OFF LIST - 587 consecutive market days: OFF LIST as of 12/24/2013 Through 11/14/2016

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TNX-601 (tianeptine oxalate) as a daytime administration for the treatment of PTSD and potential indication -neurocognitive dysfunction associated with corticosteroid use that is in pre-investigational new drug (pre-IND) application stage; and TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus, which is in pre-IND application stage. Its product pipeline also includes TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Current Quote*
Last: $0.573
Change: -0.017
Book: $0.195
Volume: 365,739

As Of: 07/19 13:15 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol TNXP

Graphs for TNXP


3 Month Graph


6 Month Graph


1 Year Graph